38 results on '"Shao, Weijuan"'
Search Results
2. Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice
- Author
-
Liu, Dinghui, Gu, Jianqiu, Shao, Weijuan, Pang, Juan, Qian, Xiaoxian, and Jin, Tianru
- Published
- 2022
- Full Text
- View/download PDF
3. Hepatic hormone FGF21 and its analogues in clinical trials
- Author
-
Shao, Weijuan and Jin, Tianru
- Published
- 2021
- Full Text
- View/download PDF
4. Moderate preventative effect with intraperitoneal liraglutide injection in high-fat diet induced C57BL/6J obese mouse model
- Author
-
Khroud, Manroop, Song, Zhuolun, Shao, Weijuan, and Jin, Tianru
- Published
- 2019
- Full Text
- View/download PDF
5. Pak1 mediates the stimulatory effect of insulin and curcumin on hepatic ChREBP expression
- Author
-
Zeng, Kejing, Tian, Lili, Sirek, Adam, Shao, Weijuan, Liu, Ling, Chiang, Yu-Ting, Chernoff, Jonathan, Ng, Dominic S, Weng, Jianping, and Jin, Tianru
- Published
- 2017
- Full Text
- View/download PDF
6. Diet Polyphenol Curcumin Stimulates Hepatic Fgf21 Production and Restores Its Sensitivity in High-Fat-Diet–Fed Male Mice
- Author
-
Zeng, Kejing, Tian, Lili, Patel, Rucha, Shao, Weijuan, Song, Zhuolun, Liu, Ling, Manuel, Justin, Ma, Xuezhong, McGilvray, Ian, Cummins, Carolyn L., Weng, Jianping, and Jin, Tianru
- Published
- 2017
7. Short‐term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice.
- Author
-
Feng, Jia Nuo, Shao, Weijuan, and Jin, Tianru
- Subjects
- *
HIGH-fat diet , *FIBROBLAST growth factors , *SEMAGLUTIDE , *LIVER cells , *ADIPOSE tissues - Abstract
Metabolic functions of GLP‐1 and its analogues have been extensively investigated. In addition to acting as an incretin and reducing body weight, we and others have suggested the existence of GLP‐1/fibroblast growth factor 21 (FGF21) axis in which liver mediates certain functions of GLP‐1 receptor agonists. In a more recent study, we found with surprise that four‐week treatment with liraglutide but not semaglutide stimulated hepatic FGF21 expression in HFD‐challenged mice. We wondered whether semaglutide can also improve FGF21 sensitivity or responsiveness and hence triggers the feedback loop in attenuating its stimulation on hepatic FGF21 expression after a long‐term treatment. Here, we assessed effect of daily semaglutide treatment in HFD‐fed mice for 7 days. HFD challenge attenuated effect of FGF21 treatment on its downstream events in mouse primary hepatocytes, which can be restored by 7‐day semaglutide treatment. In mouse liver, 7‐day semaglutide treatment stimulated FGF21 as well as genes that encode its receptor (FGFR1) and the obligatory co‐receptor (KLB), and a battery of genes that are involved in lipid homeostasis. In epididymal fat tissue, expressions of a battery genes including Klb affected by HFD challenge were reversed by 7‐day semaglutide treatment. We suggest that semaglutide treatment improves FGF21 sensitivity which is attenuated by HFD challenge. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Short-Term Curcumin Gavage Sensitizes Insulin Signaling in Dexamethasone-Treated C57BL/6 Mice1-3
- Author
-
Tian, Lili, Zeng, Kejing, Shao, Weijuan, Yang, Burton B, Fantus, George I, Weng, Jianping, and Jin, Tianru
- Published
- 2015
- Full Text
- View/download PDF
9. Liver-Specific Expression of Dominant-Negative Transcription Factor 7-Like 2 Causes Progressive Impairment in Glucose Homeostasis
- Author
-
Ip, Wilfred, Shao, Weijuan, Song, Zhuolun, Chen, Zonglan, Wheeler, Michael B., and Jin, Tianru
- Published
- 2015
- Full Text
- View/download PDF
10. Activation of cAMP Signaling Attenuates Impaired Hepatic Glucose Disposal in Aged Male p21-Activated Protein Kinase-1 Knockout Mice
- Author
-
Chiang, Yu-ting Alex, Ip, Wilfred, Shao, Weijuan, Song, Zhuolun Eric, Chernoff, Jonathan, and Jin, Tianru
- Published
- 2014
11. The Wnt Signaling Pathway Effector TCF7L2 Controls Gut and Brain Proglucagon Gene Expression and Glucose Homeostasis
- Author
-
Shao, Weijuan, Wang, Dingyan, Chiang, Yu-Ting, Ip, Wilfred, Zhu, Lingyun, Xu, Fenghao, Columbus, Joshua, Belsham, Denise D., Irwin, David M., Zhang, Haibo, Wen, Xiaoyan, Wang, Qinghua, and Jin, Tianru
- Published
- 2013
- Full Text
- View/download PDF
12. P21-Activated Protein Kinase 1 (Pak1) Mediates the Cross Talk between Insulin and β-Catenin on Proglucagon Gene Expression and Its Ablation Affects Glucose Homeostasis in Male C57BL/6 Mice
- Author
-
Chiang, Yuting Alex, Shao, Weijuan, Xu, Xiao Xue, Chernoff, Jonathan, and Jin, Tianru
- Published
- 2013
13. Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.
- Author
-
Liu, Dinghui, Pang, Juan, Shao, Weijuan, Gu, Jianqiu, Zeng, Yong, He, Housheng Hansen, Ling, Wenhua, Qian, Xiaoxian, and Jin, Tianru
- Published
- 2021
- Full Text
- View/download PDF
14. Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Diet-Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21.
- Author
-
Tian, Lili, Ning, Hongmei, Shao, Weijuan, Song, Zhuolun, Badakhshi, Yasaman, Ling, Wenhua, Yang, Burton B, Brubaker, Patricia L, and Jin, Tianru
- Subjects
LEPTIN ,GLUCAGON-like peptide 1 ,FIBROBLAST growth factors ,ANTHOCYANINS ,MICE ,GLUCOSE ,INSULIN resistance ,GLUCOSE intolerance ,RESEARCH ,FAT content of food ,GROWTH factors ,LIVER ,ANIMAL experimentation ,RESEARCH methodology ,ANIMAL nutrition ,GLYCOSIDES ,INCRETINS ,EVALUATION research ,MEDICAL cooperation ,WEIGHT gain ,COMPARATIVE studies ,WEIGHT loss ,GENES ,STATISTICAL sampling - Abstract
Background: Dietary polyphenols including anthocyanins target multiple organs.Objective: We aimed to assess the involvement of glucagon-like peptide 1 (GLP-1), leptin, insulin and fibroblast growth factor 21 (FGF21) in mediating metabolic beneficial effects of purified anthocyanin cyanidin-3-glucoside (Cy3G).Methods: Intestinal proglucagon gene (Gcg; encoding GLP-1) and liver Fgf21 expression were assessed in 6-wk-old male C57BL-6J mice fed a low-fat-diet (LFD; 10% of energy from fat), alone or with 1.6 mg Cy3G/L in drinking water for 3 wk [experiment (Exp.) 1; n = 5/group]. Similar mice were fed the LFD or a high-fat diet (HFD; 60% energy from fat) with or without Cy3G for 20 wk. Half of the mice administered Cy3G also received 4 broad-spectrum antibiotics (ABs) in drinking water between weeks 11 and 14, for a total of 6 groups (n = 8/group). Metabolic tolerance tests were conducted between weeks 2 and 16. Relevant hormone gene expression and plasma hormone concentrations were assessed mainly at the end of 20 wk (Exp. 2).Results: In Exp. 1, Cy3G administration increased ileal but not colonic Gcg level by 2-fold (P < 0.05). In Exp. 2, Cy3G attenuated HFD-induced body-weight gain (20.3% at week 16), and improved glucose tolerance (26.5% at week 15) but not insulin tolerance. Although Cy3G had no effect on glucose tolerance in LFD mice, LFD/Cy3G/AB mice showed better glucose tolerance than LFD/Cy3G mice (23%). In contrast, HFD/Cy3G/AB mice showed worse glucose tolerance compared with HFD/Cy3G mice (15%). Beneficial effects of Cy3G in HFD mice were not associated with changes in plasma leptin, insulin or GLP-1 concentrations. However, Cy3G increased hepatic Fgf21 expression in mice in Exp. 1 by 4-fold and attenuated Fgf21 overexpression in HFD mice (Exp. 2, 22%), associated with increased expression of genes that encode FGFR1 and β-klotho (>3-fold, P < 0.05).Conclusions: Dietary Cy3G may reduce body weight and exert metabolic homeostatic effects in mice via changes in hepatic FGF21. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
15. The expression of dominant negative TCF7L2 in pancreatic beta cells during the embryonic stage causes impaired glucose homeostasis
- Author
-
Shao, Weijuan, Xiong, Xiaoquan, Ip, Wilfred, Xu, Fenghao, Song, Zhuolun, Zeng, Kejing, Hernandez, Marcela, Liang, Tao, Weng, Jianping, Gaisano, Herbert, Nostro, M. Cristina, and Jin, Tianru
- Published
- 2015
- Full Text
- View/download PDF
16. The developmental Wnt signaling pathway effector β-catenin/TCF mediates hepatic functions of the sex hormone estradiol in regulating lipid metabolism.
- Author
-
Tian, Lili, Shao, Weijuan, Ip, Wilfred, Song, Zhuolun, Badakhshi, Yasaman, and Jin, Tianru
- Subjects
- *
SEX hormones , *STEROL regulatory element-binding proteins , *WNT signal transduction , *LIPID metabolism , *GROWTH factors , *WNT proteins , *ESTROGEN receptors , *ESTRADIOL - Abstract
The bipartite transcription factor β-catenin (β-cat)/T cell factor (TCF), formed by free β-cat and a given TCF family member, serves as the effector of the developmental Wnt signaling cascade. β-cat/TCFs also serve as effectors of certain peptide hormones or growth factors during adulthood. We reported that liver-specific expression of dominant-negative Transcription factor 7 like 2 (TCF7L2DN) led to impaired glucose disposal. Here we show that, in this LTCFDN transgenic mouse model, serum and hepatic lipid contents were elevated in male but not in female mice. In hepatocytes, TCF7L2DN adenovirus infection led to stimulated expression of genes that encode lipogenic transcription factors and lipogenic enzymes, while estradiol (E2) treatment attenuated the stimulation, associated with Wnt-target gene activation. Mechanistically, this E2-mediated activation can be attributed to elevated β-cat Ser675 phosphorylation and TCF expression. In wild-type female mice, ovariectomy (OVX) plus high-fat diet (HFD) challenge impaired glucose disposal and insulin tolerance, associated with increased hepatic lipogenic transcription factor sterol regulatory element-binding protein 1-c (SREBP-1c) expression. In wild-type mice with OVX, E2 reconstitution attenuated HFD-induced metabolic defects. Some of the attenuation effects, including insulin intolerance, elevated liver-weight gain, and hepatic SREBP-1c expression, were not affected by E2 reconstitution in HFD-fed LTCFDN mice with OVX. Finally, the effects of E2 in hepatocytes on β-cat/TCF activation can be attenuated by the G-protein-coupled estrogen receptor (GPER) antagonist G15. Our study thus expanded the scope of functions of the Wnt pathway effector β-cat/TCF, as it can also mediate hepatic functions of E2 during adulthood. This study also enriches our mechanistic understanding of gender differences in the risk and pathophysiology of metabolic diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Dietary Curcumin Intervention Targets Mouse White Adipose Tissue Inflammation and Brown Adipose Tissue UCP1 Expression.
- Author
-
Song, Zhuolun, Revelo, Xavier, Shao, Weijuan, Tian, Lili, Zeng, Kejing, Lei, Helena, Sun, Hong‐Shuo, Woo, Minna, Winer, Daniel, Jin, Tianru, and Sun, Hong-Shuo
- Subjects
CURCUMIN ,WHITE adipose tissue ,BROWN adipose tissue ,UNCOUPLING proteins ,LABORATORY mice ,ADIPOSE tissues ,ANIMAL experimentation ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,MICE ,RESEARCH ,RESEARCH funding ,EVALUATION research ,THERAPEUTICS - Abstract
Objective: This study aimed to determine whether dietary curcumin intervention targets both white adipose tissue (WAT) inflammation and brown adipose tissue (BAT)-mediated energy expenditure.Methods: C57BL/6J mice were fed with a low-fat diet, high-fat diet (HFD), or HFD plus curcumin. In addition to assessing the effect of curcumin intervention on metabolic profiles, this study assessed WAT macrophage infiltration and composition and inflammatory cytokine production. Metabolic cages were applied for determining energy expenditure. Raw264.7 (ATCC, Manassas, Virginia) and other cell models were utilized to test the in vitro effect of curcumin treatment.Results: Curcumin intervention reduced WAT macrophage infiltration and altered macrophage functional polarity, as the ratio of M2-like versus M1-like macrophages increased after curcumin intervention. Curcumin treatment reduced M1-like macrophage markers or proinflammation cytokine expression in both macrophages and adipocytes. Curcumin intervention also increased energy expenditure and body temperature in response to a cold challenge. Finally, the in vivo and in vitro investigations suggested that curcumin increased expression of uncoupling protein 1 (UCP1), possibly involving PPAR-dependent and -independent mechanisms.Conclusions: Curcumin intervention targets both WAT inflammation and BAT UCP1 expression. These observations advanced our knowledge on the metabolic beneficial effects of the curry compound curcumin, bringing us a novel perspective on dietary polyphenol research. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. Urban Railway Network Traffic Prediction with Spatiotemporal Correlations Matrix.
- Author
-
Shao, Weijuan and Li, Man
- Published
- 2016
- Full Text
- View/download PDF
19. Short-Term Curcumin Gavage Sensitizes Insulin Signaling in Dexamethasone-Treated C57BL/6 Mice.
- Author
-
Lili Tian, Kejing Zeng, Weijuan Shao, Yang, Burton B., Fantus, I. George, Jianping Weng, Tianru Jin, Tian, Lili, Zeng, Kejing, Shao, Weijuan, Weng, Jianping, and Jin, Tianru
- Subjects
THERAPEUTIC use of antioxidants ,BLOOD sugar analysis ,ANIMAL experimentation ,ANTIOXIDANTS ,CELL culture ,CELLULAR signal transduction ,DIETARY supplements ,EPITHELIAL cells ,GENES ,GLUCOCORTICOIDS ,GROWTH factors ,INSULIN ,INSULIN resistance ,LIVER ,MENTAL health surveys ,METABOLISM ,MICE ,PREDIABETIC state ,RECOMBINANT proteins ,RESEARCH funding ,STATISTICAL sampling ,DEXAMETHASONE ,CHEMICAL inhibitors ,CURCUMIN ,PREVENTION ,THERAPEUTICS - Abstract
Background: Long-term dietary curcumin (>12 wk) improves metabolic homeostasis in obese mice by sensitizing insulin signaling and reducing hepatic gluconeogenesis. Whether these occur only secondary to its chronic anti-inflammatory and antioxidative functions is unknown.Objective: In this study, we assessed the insulin sensitization effect of short-term curcumin gavage in a rapid dexamethasone-induced insulin resistance mouse model, in which the chronic anti-inflammatory function is eliminated.Methods: Six-week-old male C57BL/6 mice received an intraperitoneal injection of dexamethasone (100 mg/kg body weight) or phosphate-buffered saline every day for 5 d, with or without simultaneous curcumin gavage (500 mg/kg body weight). On day 7, insulin tolerance tests were performed. After a booster dexamethasone injection and curcumin gavage on day 8, blood glucose and insulin concentrations were measured. Liver tissues were collected on day 10 for quantitative polymerase chain reaction and Western blotting to assess gluconeogenic gene expression, insulin signaling, and the expression of fibroblast growth factor 21 (FGF21). Primary hepatocytes from separate, untreated C57BL/6 mice were used for testing the in vitro effect of curcumin treatment.Results: Dexamethasone injection impaired insulin tolerance (P < 0.05) and elevated ambient plasma insulin concentrations by ~2.7-fold (P < 0.01). Concomitant curcumin administration improved insulin sensitivity and reduced hepatic gluconeogenic gene expression. The insulin sensitization effect of curcumin was demonstrated by increased stimulation of S473 phosphorylation of protein kinase B (P < 0.01) in the dexamethasone-treated mouse liver, as well as the repression of glucose production in primary hepatocytes (P < 0.001). Finally, curcumin gavage increased FGF21 expression by 2.1-fold in the mouse liver (P < 0.05) and curcumin treatment increased FGF21 expression in primary hepatocytes.Conclusion: These observations suggest that the early beneficial effect of curcumin intervention in dexamethasone-treated mice is the sensitization of insulin signaling, involving the stimulation of FGF21 production, a known insulin sensitizer. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
20. TCF7L2 and Wnt Signalling Positively Regulate Leptin Gene Expression in Adipocytes
- Author
-
Chen, Zonglan, Shao, Weijuan, Song, Zhuolun, Lu, Huogen, Fantus, I George, Xu, Fen, Weng, Jianping, and Jin, Tianru
- Published
- 2014
- Full Text
- View/download PDF
21. Cyclic AMP signaling stimulates proteasome degradation of thioredoxin interacting protein (TxNIP) in pancreatic β-cells
- Author
-
Shao, Weijuan, Yu, Zhiwen, Fantus, I George, and Jin, Tianru
- Subjects
- *
CYCLIC adenylic acid , *LABORATORY rats , *GENE expression , *PROTEIN-protein interactions , *PANCREATIC beta cells , *CELL lines , *GLUCOSE , *CHLOROQUINE , *CELLULAR signal transduction - Abstract
Abstract: Thioredoxin interacting protein (TxNIP) functions as an effector of glucotoxicity in pancreatic β-cells. Exendin-4 (Ex-4), a long-term effective GLP-1 receptor agonist, reduces TxNIP level in pancreatic β-cells. Mechanisms underlying this reduction, however, remain largely unknown. We show here that Ex-4, 8-bromo-cAMP, the cAMP promoting agent forskolin, as well as activators of protein kinase A (PKA) and exchange protein activated by cAMP (Epac), all attenuated the effect of high glucose (20mM) on TxNIP level in the pancreatic β-cell line Ins-1. Forskolin and Ex-4 also reduced TxNIP level in cultured primary rat islets. This repressive effect is at least partially mediated via stimulating proteasome-dependent TxNIP degradation, since the proteasomal inhibitor MG132, but not the lysosomal inhibitor chloroquine, significantly blocked the repressive effect of forskolin. Furthermore, forskolin enhanced TxNIP ubiquitination. Both PKA inhibition and Epac inhibition partially blocked the repressive effect of forskolin on TxNIP level. In addition, forskolin and Ex-4 protected Ins-1 cells from high glucose-induced apoptotic activity, assessed by measuring caspase 3 activity. Finally, knockdown of TxNIP expression led to reduced caspase 3 expression levels and blunted response to forskolin treatment. We suggest that proteasome-dependent TxNIP degradation is a novel mechanism by which Ex-4-cAMP signaling protects pancreatic β cells. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
22. Wnt Signaling and Transcription Factor 7-Like 2 Mediate the Effect of Insulin in Repressing Hepatic Gluconeogenesis
- Author
-
Ip, Wilfred, Shao, Weijuan, Chiang, Yu-Ting A., and Jin, Tianru
- Published
- 2012
- Full Text
- View/download PDF
23. 1837-P: Female Hormone Estradiol Regulates Hepatic FGF21 Expression via Wnt Pathway Activation.
- Author
-
SHAO, WEIJUAN, BADAKHSHI, YASAMAN, and JIN, TIANRU
- Abstract
β-cat/TCF, formed by β-cat and a TCF family member, serves as the effector of the developmental canonical Wnt signaling cascade. β-cat/TCFs can also function as effectors of metabolic hormones or growth factors during adulthood. We have demonstrated recently that liver-specific expression of dominant-negative TCF7L2 (TCF7L2DN) led to impaired glucose disposal in both male and female mice. Increased hepatic lipogenesis, however, was observed in male but not in female mice. Our further investigations on such LTCFDN transgenic mouse model revealed the role of estradiol (E2) in stimulating β-cat/TCF activity. E2 reconstitution in WT mice with ovariectomy (OVX) restored the resistance of female mice to HFD induced body weight gain, insulin intolerance and elevation of hepatic lipogenic gene expression. Such beneficial effects of E2 reconstitution, however, were absent in LTCFDN female mice. To identify downstream metabolic effector/s of Wnt signaling in regulating hepatic lipogenesis, we assessed metabolic hormone expression in LTCFDN and WT littermates. Curiously, hepatic but not adipose tissue FGF-21 level was reduced in male LTCFDN mice. We then directly assessed the effect of E2 on hepatic FGF-21 expression. In WT mice on LFD diet, OVX leads to reduced hepatic FGF-21 mRNA and protein levels, associated with reduced circulating FGF-21 hormone level. These reduction was associated with reduced hepatic β-cat S675 phosphorylation, TCF7 and TCF7L2 expression. In WT mice on HFD, OVX also reduced hepatic FGF-21 mRNA and circulating FGF-21 hormone levels. Such reduction was also restored with E2 reconstitution. Our study hence identified that FGF-21 is likely among the downstream effectors of E2-Wnt signaling cascade in hepatic lipid homeostasis. Disclosure: W. Shao: None. Y. Badakhshi: None. T. Jin: None. Funding: Canadian Institutes of Health Research (PJT159735) [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. 370-OR: Hepatic FGF21 Expression Is Under the Regulation of the Canonical Wnt Signaling Pathway.
- Author
-
BADAKHSHI, YASAMAN, SHAO, WEIJUAN, TIAN, LILI, and JIN, TIANRU
- Abstract
The metabolic hormone FGF-21 is mainly produced and released from the liver in response to nutritional stresses such as starvation, alcohol or ketogenic diet consumption. Body weight lowering and insulin signaling sensitization effects of FGF-21 and its analogues have been demonstrated in animal models or in human subjects. We show here that hepatic FGF-21 mRNA and FGF-21 protein levels were reduced in male LTCFDN, a transgenic mouse line in which canonical Wnt signaling cascade is functionally attenuated due to the expression of dominant negative transcription factor TCF7L2 in the liver, and the reduction is not associated with reduced expression of PPARα, a key transactivator of FGF-21. Furthermore, starvation-induced plasma FGF-21 elevation was also attenuated in male LTCFDN mice. Utilizing mouse primary hepatocytes, we found that FGF-21 mRNA and FGF-21 protein expression can be increased by Wnt-3a or LiCl treatment. Two evolutionarily conserved TCF binding motifs (TCFB) were then located within the mouse FGF-21 gene promoter. Luciferase and ChIP results suggest that one of them is responsible for β-cat/TCF mediated activation on FGF-21 transcription.It has been shown recently that in mouse brain tanycytes, FGF-21 secretion can be induced by palmitate treatment. We found that in mouse primary hepatocytes, palmitate but not oleate treatment increased expression of the Wnt target gene Ccnd1, which encodes cyclin D1. Our observations hence suggest that Wnt signaling cascade is involved in hepatic FGF-21 production and secretion, and the positive regulation is likely independent of fibrate/PPARα-mediated induction. Investigations on this novel hepatic signaling axis will strengthen our knowledge on the physiologically significant hormone FGF-21, leading to novel therapeutic avenues in treating impaired metabolism. Disclosure: Y. Badakhshi: None. W. Shao: None. L. Tian: None. T. Jin: None. Funding: Canadian Institutes of Health Research (PJT159735) [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Curcumin represses mouse 3T3-L1 cell adipogenic differentiation via inhibiting miR-17-5p and stimulating the Wnt signalling pathway effector Tcf7l2.
- Author
-
Tian, Lili, Song, Zhuolun, Shao, Weijuan, Du, William W, Zhao, Lisa R, Zeng, Kejing, Yang, Burton B, and Jin, Tianru
- Published
- 2017
- Full Text
- View/download PDF
26. Liraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue.
- Author
-
Gu J, Shao W, Liu D, Feng JN, Pang J, and Jin T
- Subjects
- Adipogenesis genetics, Animals, Glucagon-Like Peptide 1 pharmacology, Mice, Mice, Inbred C57BL, Rats, Wnt Signaling Pathway, Liraglutide pharmacology, Liraglutide therapeutic use, beta Catenin genetics, beta Catenin metabolism
- Abstract
Although canonical Wnt signaling pathway activation was shown to negatively regulate adipogenesis, recent investigations suggest that Wnt pathway effectors TCF7L2 and β-catenin (β-cat) in adipose tissues are also involved in energy homeostasis during adulthood. In assessing the metabolic beneficial effect of GLP-1-based diabetes drugs in high-fat diet (HFD)-challenged mice, we observed that liraglutide treatment affected the expression of a battery of adipose tissue-specific genes, including those that encode adiponectin and leptin, mainly in epididymal white adipose tissue (eWAT). Fourteen-week HFD challenge repressed TCF7L2 and β-cat S675 phosphorylation in eWAT, while such repression was reversed by liraglutide treatment (150 µg/kg body weight daily) during weeks 10-14. In Glp1r-/-mice, liraglutide failed in stimulating TCF7L2 or β-cat in eWAT. We detected Glp1r expression in mouse eWAT and its level is enriched in its stromal vascular fraction (SVF). Mouse eWAT-SVF showed reduced expression of Tcf7l2 and its Tcf7l2 level could not be stimulated by liraglutide treatment; while following adipogenic differentiation, rat eWAT-SVF showed elevated Tcf7l2 expression. Direct in vitro liraglutide treatment in eWAT-SVF stimulated CREB S133, β-cat S675 phosphorylation, and cellular cAMP level. Thus, cAMP/β-cat signaling cascade can be stimulated by liraglutide in eWAT via GLP-1R expressed in eWAT-SVF.
- Published
- 2022
- Full Text
- View/download PDF
27. Hepatic hormone FGF21 and its analogues in clinical trials.
- Author
-
Shao W and Jin T
- Abstract
Fibroblast growth factor 21 (FGF21) is a fasting or stress inducible metabolic hormone produced mainly in the liver. It plays important roles in regulating both glucose and lipid homeostasis via interacting with a heterodimeric receptor complex comprising FGF receptor 1 (FGFR1) and β-klotho (KLB). For the past decade, great effort has been made on developing FGF21 derivatives or specific FGF21 receptor agonists into therapeutic agents for various metabolic disorders including type 2 diabetes (T2D), obesity, and more importantly, nonalcoholic fatty liver disease (NAFLD). Here we have reviewed FGF21 gene and protein structures, its expression pattern, cellular signaling cascades that mediate FGF21 production and function. We have then summarized the six clinical trials utilizing four FGF21 analogues. Finally, two recent literatures on the development of GLP-1 and FGF21 dual agonists were presented briefly., Competing Interests: The authors declare no conflict of interest., (© 2022 The Authors. Chronic Diseases and Translational Medicine published by John Wiley & Sons, Ltd on behalf of Chinese Medical Association.)
- Published
- 2022
- Full Text
- View/download PDF
28. Estrogen-Wnt signaling cascade regulates expression of hepatic fibroblast growth factor 21.
- Author
-
Badakhshi Y, Shao W, Liu D, Tian L, Pang J, Gu J, Hu J, and Jin T
- Subjects
- Animals, Cells, Cultured, Estrogens metabolism, Female, Gene Expression Regulation, Hepatocytes metabolism, Male, Mice, Mice, Transgenic, PPAR alpha metabolism, Fibroblast Growth Factors metabolism, Liver metabolism, Wnt Signaling Pathway
- Abstract
We have generated the transgenic mouse line LTCFDN in which dominant negative TCF7L2 (TCF7L2DN) is specifically expressed in the liver during adulthood. Male but not female LTCFDN mice showed elevated hepatic and plasma triglyceride (TG) levels, indicating the existence of estrogen-β-cat/TCF signaling cascade that regulates hepatic lipid homeostasis. We show here that hepatic fibroblast growth factor 21 (FGF21) expression was reduced in male but not in female LTCFDN mice. The reduction was not associated with altered hepatic expression of peroxisome proliferator-activated receptor α (PPARα). In mouse primary hepatocytes (MPH), Wnt-3a treatment increased FGF21 expression in the presence of PPARα inhibitor. Results from our luciferase-reporter assay and chromatin immunoprecipitation suggest that evolutionarily conserved TCF binding motifs (TCFBs) on Fgf21 promoter mediate Wnt-3a-induced Fgf21 transactivation. Female mice showed reduced hepatic FGF21 production and circulating FGF21 level following ovariectomy (OVX), associated with reduced hepatic TCF expression and β-catenin S675 phosphorylation. Finally, in MPH, estradiol (E2) treatment enhanced FGF21 expression, as well as binding of TCF7L2 and ribonucleic acid (RNA) polymerase II to the Fgf21 promoter; and the enhancement can be attenuated by the G-protein-coupled estrogen receptor 1 (GPER) antagonist G15. Our observations hence indicate that hepatic FGF21 is among the effectors of the newly recognized E2-β-cat/TCF signaling cascade. NEW & NOTEWORTHY FGF21 is mainly produced in the liver. Therapeutic effect of FGF21 analogues has been demonstrated in clinical trials on reducing hyperlipidemia. We show here that Fgf21 transcription is positively regulated by Wnt pathway effector β-cat/TCF. Importantly, hepatic β-cat/TCF activity can be regulated by the female hormone estradiol, involving GPER. The investigation enriched our understanding on hepatic FGF21 hormone production, and expanded our view on metabolic functions of the Wnt pathway in the liver.
- Published
- 2021
- Full Text
- View/download PDF
29. Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein.
- Author
-
Zhou W, Shao W, Zhang Y, Liu D, Liu M, and Jin T
- Subjects
- Acute Lung Injury chemically induced, Acute Lung Injury metabolism, Animals, Bronchoalveolar Lavage Fluid, Cytokines metabolism, Glucagon-Like Peptide 1 metabolism, Inflammasomes, Lipopolysaccharides, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Organ Size, Acute Lung Injury prevention & control, Carrier Proteins metabolism, Glucagon-Like Peptide-1 Receptor metabolism, Hypoglycemic Agents therapeutic use, Liraglutide therapeutic use, Thioredoxins metabolism
- Abstract
Repurposing clinically used drugs is among the important strategies in drug discovery. Glucagon-like peptide-1 (GLP-1) and its diabetes-based drugs, such as liraglutide, possess a spectrum of extra-pancreatic functions, while GLP-1 receptor (GLP-1R) is most abundantly expressed in the lung. Recent studies have suggested that GLP-1-based drugs exert beneficial effects in chronic, as well as acute, lung injury rodent models. Here, we show that liraglutide pretreatment reduced LPS induced acute lung injury in mice. It significantly reduced lung injury score, wet/dry lung weight ratio, bronchoalveolar lavage fluid immune cell count and protein concentration, and cell apoptosis in the lung, and it was associated with reduced lung inflammatory cytokine and chemokine gene expression. Importantly, these effects were virtually absent in GLP-1R
-/- mice. A well-known function of GLP-1 and GLP-based drugs in pancreatic β-cells is the attenuation of high-glucose stimulated expression of thioredoxin-interacting protein (TxNIP), a key component of inflammasome. LPS-challenged lungs showed elevated TxNIP mRNA and protein expression, which was attenuated by liraglutide treatment in a GLP-1R-dependent manner. Hence, our observations suggest that GLP-1R is essential in mediating beneficial effects of liraglutide in acute lung injury, with the inflammasome component TxNIP as a potential target.- Published
- 2020
- Full Text
- View/download PDF
30. GABA requires GLP-1R to exert its pancreatic function during STZ challenge.
- Author
-
Shao W, Liu W, Liang P, Song Z, Israel O, Prud'homme GJ, Wang Q, and Jin T
- Subjects
- Animals, Caspase 3 metabolism, Cell Line, Glucagon-Like Peptide-1 Receptor genetics, Homeodomain Proteins genetics, Homeodomain Proteins metabolism, Humans, Maf Transcription Factors, Large genetics, Maf Transcription Factors, Large metabolism, Male, Mice, Mice, Knockout, Phosphorylation, Trans-Activators genetics, Trans-Activators metabolism, beta Catenin metabolism, Glucagon-Like Peptide-1 Receptor metabolism, Insulin-Secreting Cells metabolism, gamma-Aminobutyric Acid metabolism
- Abstract
Gamma-aminobutyric acid (GABA) administration attenuates streptozotocin (STZ)-induced diabetes in rodent models with unclear underlying mechanisms. We found that GABA and Sitagliptin possess additive effect on pancreatic β-cells, which prompted us to ask the existence of common or unique targets of GLP-1 and GABA in pancreatic β-cells. Effect of GABA on expression of thioredoxin-interacting protein (TxNIP) was assessed in the INS-1 832/13 (INS-1) cell line, WT and GLP-1R-/- mouse islets. GABA was also orally administrated in STZ-challenged WT or GLP-1R-/- mice, followed by immunohistochemistry assessment of pancreatic islets. Effect of GABA on Wnt pathway effector β-catenin (β-cat) was examined in INS-1 cells, WT and GLP-1R-/- islets. We found that GABA shares a common feature with GLP-1 on inhibiting TxNIP, while this function was attenuated in GLP-1R-/- islets. In WT mice with STZ challenge, GABA alleviated several 'diabetic syndromes', associated with increased β-cell mass. These features were virtually absent in GLP-1R-/- mice. Knockdown TxNIP in INS-1 cells increased GLP-1R, Pdx1, Nkx6.1 and Mafa levels, associated with increased responses to GABA or GLP-1 on stimulating insulin secretion. Cleaved caspase-3 level can be induced by high-glucose, dexamethasone, or STZ in INS-1 cell, while GABA treatment blocked the induction. Finally, GABA treatment increased cellular cAMP level and β-cat S675 phosphorylation in WT but not GLP-1R-/- islets. We, hence, identified TxNIP as a common target of GABA and GLP-1 and suggest that, upon STZ or other stress challenge, the GLP-1R-cAMP-β-cat signaling cascade also mediates beneficial effects of GABA in pancreatic β-cell, involving TxNIP reduction.
- Published
- 2020
- Full Text
- View/download PDF
31. The LIM homeodomain protein ISL1 mediates the function of TCF7L2 in pancreatic beta cells.
- Author
-
Shao W, Szeto V, Song Z, Tian L, Feng ZP, Nostro MC, and Jin T
- Subjects
- Animals, Cell Line, Chromatin Immunoprecipitation, Glucagon-Like Peptide 1 pharmacology, Insulin metabolism, LIM-Homeodomain Proteins genetics, Male, Mice, Phosphorylation drug effects, Promoter Regions, Genetic genetics, Protein Binding, Rats, Transcription Factor 7-Like 2 Protein genetics, Insulin-Secreting Cells drug effects, Insulin-Secreting Cells metabolism, LIM-Homeodomain Proteins metabolism, Transcription Factor 7-Like 2 Protein metabolism
- Abstract
Pancreatic β-cell Tcf7l2 deletion or its functional knockdown suggested the essential role of this Wnt pathway effector in controlling insulin secretion, glucose homeostasis and β-cell gene expression. As the LIM homeodomain protein ISL1 is a suggested Wnt pathway downstream target, we hypothesize that it mediates metabolic functions of TCF7L2. We aimed to determine the role of ISL1 in mediating the function of TCF7L2 and the incretin hormone GLP-1 in pancreatic β-cells. The effect of dominant negative TCF7L2 (TCF7L2DN) mediated Wnt pathway functional knockdown on Isl1 expression was determined in βTCFDN mouse islets and in the rat insulinoma cell line INS-1 832/13. Luciferase reporter assay and chromatin immunoprecipitation were utilized to determine whether Isl1 is a direct downstream target of Tcf7l2 TCF7L2DN adenovirus infection and siRNA-mediated Isl1 knockdown on β-cell gene expression were compared. Furthermore, Isl1 knockdown on GLP-1 stimulated β-catenin S675 phosphorylation and insulin secretion was determined. We found that TCF7L2DN repressed ISL1 levels in βTCFDN islets and the INS-1 832/13 cell line. Wnt stimulators enhanced Isl1 promoter activity and binding of TCF7L2 on Isl1 promoter. TCF7L2DN adenovirus infection and Isl1 knockdown generated similar repression on expression of β-cell genes, including the ones that encode GLUT2 and GLP-1 receptor. Either TCF7L2DN adenovirus infection or Isl1 knockdown attenuated GLP-1-stimulated β-catenin S675 phosphorylation in INS-1 832/13 cells or mouse islets and GLP-1 stimulated insulin secretion in INS-1 832/13 or MIN6 cells. Our observations support the existence of TCF7L2-ISL1 transcriptional network, and we suggest that this network also mediates β-cell function of GLP-1., (© 2018 Society for Endocrinology.)
- Published
- 2018
- Full Text
- View/download PDF
32. GLP-1-derived nonapeptide GLP-1(28-36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice.
- Author
-
Ip W, Shao W, Chiang YT, and Jin T
- Subjects
- Animals, Body Weight drug effects, Cells, Cultured, Down-Regulation drug effects, Down-Regulation genetics, Drug-Related Side Effects and Adverse Reactions prevention & control, Gene Expression drug effects, Gluconeogenesis genetics, Glucose Tolerance Test, Liver metabolism, Male, Mice, Mice, Inbred C57BL, Pyruvic Acid metabolism, Diet, High-Fat adverse effects, Glucagon-Like Peptide 1 pharmacology, Gluconeogenesis drug effects, Liver drug effects, Peptide Fragments pharmacology, Pyruvic Acid adverse effects
- Abstract
Certain "degradation" products of GLP-1 were found to possess beneficial effects on metabolic homeostasis. Here, we investigated the function of the COOH-terminal fragment of GLP-1, the nonapeptide GLP-1(28-36)amide, in hepatic glucose metabolism. C57BL/6 mice fed a high-fat diet (HFD) for 13 wk were injected intraperitoneally with GLP-1(28-36)amide for 6 wk. A significant reduction in body weight gain in response to HFD feeding was observed in GLP-1(28-36)amide-treated mice. GLP-1(28-36)amide administration moderately improved glucose disposal during glucose tolerance test but more drastically attenuated glucose production during pyruvate tolerance test, which was associated with reduced hepatic expression of the gluconeogenic genes Pck1, G6pc, and Ppargc1a. Mice treated with GLP-1(28-36)amide exhibited increased phosphorylation of PKA targets, including cAMP response element-binding protein (CREB), ATF-1, and β-catenin. In primary hepatocytes, GLP-1(28-36)amide reduced glucose production and expression of Pck1, G6pc, and Ppargc1a, which was associated with increased cAMP content and PKA target phosphorylation. These effects were attenuated by PKA inhibition. We suggest that GLP-1(28-36)amide represses hepatic gluconeogenesis involving the activation of components of the cAMP/PKA signaling pathway. This study further confirmed that GLP-1(28-36)amide possesses therapeutic potential for diabetes and other metabolic disorders.
- Published
- 2013
- Full Text
- View/download PDF
33. GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.
- Author
-
Shao W, Wang Z, Ip W, Chiang YT, Xiong X, Chai T, Xu C, Wang Q, and Jin T
- Subjects
- Animals, Blood Glucose metabolism, Cell Line, Cyclic AMP metabolism, Diabetes Mellitus, Experimental metabolism, Diabetes Mellitus, Experimental pathology, Disease Models, Animal, Drug Design, Hyperglycemia drug therapy, Hyperglycemia metabolism, Hyperglycemia pathology, In Vitro Techniques, Insulin-Secreting Cells cytology, Insulin-Secreting Cells enzymology, Male, Mice, Mice, Inbred C57BL, Protein Kinase C beta metabolism, Rats, Signal Transduction physiology, Blood Glucose drug effects, Diabetes Mellitus, Experimental drug therapy, Glucagon-Like Peptide 1 pharmacology, Insulin-Secreting Cells drug effects, Peptide Fragments pharmacology, Signal Transduction drug effects
- Abstract
Recent studies have demonstrated that the COOH-terminal fragment of the incretin hormone glucagon-like peptide-1 (GLP-1), a nonapeptide GLP-1(28-36)amide, attenuates diabetes and hepatic steatosis in diet-induced obese mice. However, the effect of this nonapeptide in pancreatic β-cells remains largely unknown. Here, we show that in a streptozotocin-induced mouse diabetes model, GLP-1(28-36)amide improved glucose disposal and increased pancreatic β-cell mass and β-cell proliferation. An in vitro investigation revealed that GLP-1(28-36)amide stimulates β-catenin (β-cat) Ser(675) phosphorylation in both the clonal INS-1 cell line and rat primary pancreatic islet cells. In INS-1 cells, the stimulation was accompanied by increased nuclear β-cat content. GLP-1(28-36)amide was also shown to increase cellular cAMP levels, PKA enzymatic activity, and cAMP response element-binding protein (CREB) and cyclic AMP-dependent transcription factor-1 (ATF-1) phosphorylation. Furthermore, GLP-1(28-36)amide treatment enhanced islet insulin secretion and increased the growth of INS-1 cells, which was associated with increased cyclin D1 expression. Finally, PKA inhibition attenuated the effect of GLP-1(28-36)amide on β-cat Ser(675) phosphorylation and cyclin D1 expression in the INS-1 cell line. We have thus revealed the beneficial effect of GLP-1(28-36)amide in pancreatic β-cells in vitro and in vivo. Our observations suggest that GLP-1(28-36)amide may exert its effect through the PKA/β-catenin signaling pathway.
- Published
- 2013
- Full Text
- View/download PDF
34. New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin.
- Author
-
Xiong X, Shao W, and Jin T
- Subjects
- Animals, Diabetes Mellitus metabolism, Gastric Inhibitory Polypeptide metabolism, Humans, Glucagon-Like Peptide 1 metabolism, Insulin-Secreting Cells metabolism, Wnt Signaling Pathway physiology, beta Catenin metabolism
- Abstract
During the past two decades, the exploration of function of two incretin hormones, namely glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), has led to the development of two categories of novel therapeutic agents for diabetes and its complications, known as GLP-1 receptor (GLP-1R) agonists and DPP-IV inhibitors. Mechanisms underlying the function of GLP-1, however, still need to be further explored. GLP-1 not only functions as an incretin hormone in stimulating insulin secretion in response to nutritional, hormonal and neuronal stimulations, but also acts as an "insulin-like" factor in β-cell and extra-pancreatic organs. In addition to these insulinotropic and insulinomimetic effects, GLP-1 was shown to exert its protective effect in β-cell by repressing the expression of TxNIP, a mediator of glucolipotoxicity. A number of recent studies have shown that the Wnt signaling pathway effector, the bipartite transcription factor β-catenin/TCF, controls not only the production of GLP-1, but also the function of GLP-1. Furthermore, previously assumed "degradation" products of GLP-1(7-36)amide, including GLP-1(9-36)amide and GLP-1(28-36)amide, have been shown to exert beneficial effect in pancreas and extra-pancreatic tissues or cell lineages. Here we summarized our current knowledge on the metabolic, proliferative and protective effects of GLP-1(7-36)amide and its cleavage fragments, mainly focusing on pancreatic β-cells and the involvement of the Wnt signaling pathway effector β-catenin.
- Published
- 2012
- Full Text
- View/download PDF
35. The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis.
- Author
-
Ip W, Shao W, Chiang YT, and Jin T
- Subjects
- Animals, Cell Line, Tumor, Cells, Cultured, Down-Regulation drug effects, Gene Silencing, Hepatocytes cytology, Hepatocytes metabolism, Humans, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Phosphorylation drug effects, Postprandial Period, Protein Processing, Post-Translational drug effects, RNA, Messenger metabolism, Transcription Factor 7-Like 2 Protein antagonists & inhibitors, Transcription Factor 7-Like 2 Protein genetics, Up-Regulation drug effects, Gluconeogenesis drug effects, Hepatocytes drug effects, Hypoglycemic Agents pharmacology, Insulin pharmacology, Transcription Factor 7-Like 2 Protein metabolism, Wnt Signaling Pathway drug effects
- Abstract
Certain single nucleotide polymorphisms (SNPs) in transcription factor 7-like 2 (TCF7L2) are strongly associated with the risk of type 2 diabetes. TCF7L2 and β-catenin (β-cat) form the bipartite transcription factor cat/TCF in stimulating Wnt target gene expression. cat/TCF may also mediate the effect of other signaling cascades, including that of cAMP and insulin in cell-type specific manners. As carriers of TCF7L2 type 2 diabetes risk SNPs demonstrated increased hepatic glucose production, we aimed to determine whether TCF7L2 expression is regulated by nutrient availability and whether TCF7L2 and Wnt regulate hepatic gluconeogenesis. We examined hepatic Wnt activity in the TOPGAL transgenic mouse, assessed hepatic TCF7L2 expression in mice upon feeding, determined the effect of insulin on TCF7L2 expression and β-cat Ser⁶⁷⁵ phosphorylation, and investigated the effect of Wnt activation and TCF7L2 knockdown on gluconeogenic gene expression and glucose production in hepatocytes. Wnt activity was observed in pericentral hepatocytes in the TOPGAL mouse, whereas TCF7L2 expression was detected in human and mouse hepatocytes. Insulin and feeding stimulated hepatic TCF7L2 expression in vitro and in vivo, respectively. In addition, insulin activated β-cat Ser⁶⁷⁵ phosphorylation. Wnt activation by intraperitoneal lithium injection repressed hepatic gluconeogenic gene expression in vivo, whereas lithium or Wnt-3a reduced gluconeogenic gene expression and glucose production in hepatic cells in vitro. Small interfering RNA-mediated TCF7L2 knockdown increased glucose production and gluconeogenic gene expression in cultured hepatocytes. These observations suggest that Wnt signaling and TCF7L2 are negative regulators of hepatic gluconeogenesis, and TCF7L2 is among the downstream effectors of insulin in hepatocytes.
- Published
- 2012
- Full Text
- View/download PDF
36. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes.
- Author
-
Shao W, Yu Z, Chiang Y, Yang Y, Chai T, Foltz W, Lu H, Fantus IG, and Jin T
- Subjects
- Adipocytes drug effects, Adipocytes metabolism, Adipose Tissue drug effects, Adipose Tissue metabolism, Adipose Tissue pathology, Adiposity drug effects, Animals, Curcumin administration & dosage, Dietary Fats pharmacology, Dietary Supplements, Gene Expression Regulation drug effects, Glucose metabolism, Hep G2 Cells, Humans, Inflammation genetics, Insulin pharmacology, Lipogenesis genetics, Liver drug effects, Liver pathology, Male, Mice, Mice, Inbred C57BL, Obesity metabolism, Phosphorylation drug effects, Proto-Oncogene Proteins c-akt metabolism, Rats, Signal Transduction drug effects, Time Factors, Weight Gain drug effects, Adipocytes pathology, Curcumin pharmacology, Inflammation pathology, Insulin Resistance, Lipogenesis drug effects, Liver metabolism, Obesity prevention & control
- Abstract
Background: Mechanisms underlying the attenuation of body weight gain and insulin resistance in response to high fat diet (HFD) by the curry compound curcumin need to be further explored. Although the attenuation of the inflammatory pathway is an accepted mechanism, a recent study suggested that curcumin stimulates Wnt signaling pathway and hence suppresses adipogenic differentiation. This is in contrast with the known repressive effect of curcumin on Wnt signaling in other cell lineages., Methodology and Principal Findings: We conducted the examination on low fat diet, or HFD fed C57BL/6J mice with or without curcumin intervention for 28 weeks. Curcumin significantly attenuated the effect of HFD on glucose disposal, body weight/fat gain, as well as the development of insulin resistance. No stimulatory effect on Wnt activation was observed in the mature fat tissue. In addition, curcumin did not stimulate Wnt signaling in vitro in primary rat adipocytes. Furthermore, curcumin inhibited lipogenic gene expression in the liver and blocked the effects of HFD on macrophage infiltration and the inflammatory pathway in the adipose tissue., Conclusions and Significance: We conclude that the beneficial effect of curcumin during HFD consumption is mediated by attenuating lipogenic gene expression in the liver and the inflammatory response in the adipose tissue, in the absence of stimulation of Wnt signaling in mature adipocytes.
- Published
- 2012
- Full Text
- View/download PDF
37. Insulin treatment and high-fat diet feeding reduces the expression of three Tcf genes in rodent pancreas.
- Author
-
Columbus J, Chiang Y, Shao W, Zhang N, Wang D, Gaisano HY, Wang Q, Irwin DM, and Jin T
- Subjects
- Animals, Base Sequence, Cell Line, DNA Primers genetics, Diabetes Mellitus, Type 2 etiology, Dietary Fats toxicity, Down-Regulation drug effects, Female, Hepatocyte Nuclear Factor 1-alpha, Humans, In Vitro Techniques, Insulin metabolism, Insulin-Secreting Cells drug effects, Insulin-Secreting Cells metabolism, Mice, Mice, Transgenic, Pregnancy, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Rats, Wistar, Signal Transduction, T Cell Transcription Factor 1 genetics, TCF Transcription Factors metabolism, Transcription Factor 7-Like 1 Protein, Transcription Factor 7-Like 2 Protein, Wnt Proteins metabolism, Dietary Fats administration & dosage, Insulin pharmacology, Pancreas drug effects, Pancreas metabolism, TCF Transcription Factors genetics
- Abstract
Specific single-nucleotide polymorphisms in intronic regions of human TCF7L2 are associated with an elevated risk of developing type 2 diabetes. Whether Tcf7l2 is expressed in pancreatic islets of rodent species at a considerable level, however, remains controversial. We used RT-PCR and quantitative RT-PCR to examine Tcf7l2 expression in rodent gut, pancreas, isolated pancreatic islets, and cultured cell lines. The expression level of Tcf7l2 was relatively lower in the pancreas compared to the gut or the pancreatic β-cell line Ins-1. Immunostaining did not detect a Tcf7l2 signal in mouse pancreatic islets. Endogenous canonical Wnt activity was not appreciable in the pancreas of TOPGAL transgenic mice. Both Tcf7 and Tcf7l1, but not Lef1, were expressed in the pancreas. The expression of the three Tcf genes (Tcf7, Tcf7l1, and Tcf7l2) in the pancreas was reduced by treatment with insulin or high-fat diet feeding, in contrast to the stimulation of Tcf7l2 expression by insulin in the gut. We suggest that hyperinsulinemia represses Tcf gene expression in the pancreas. Whether and how this reduction alters the function of pancreatic β cells during hyperinsulinemia deserves further investigation.
- Published
- 2010
- Full Text
- View/download PDF
38. Tissue-specific effect of dietary cysteamine on expression of adiponectin receptors in rats.
- Author
-
Xu J, Shao W, Chi H, Tan Y, and Zhao R
- Subjects
- Animals, Male, RNA, Messenger analysis, Rats, Rats, Wistar, Tissue Distribution, Cysteamine pharmacology, Diet, Gene Expression drug effects, Receptors, Adiponectin genetics
- Abstract
Adiponectin is synthesized by adipocytes and affects glucose and lipid metabolism by binding to its receptors, AdipoR1 and AdipoR2. Cysteamine, a naturally existing intermediate metabolite of sulfur amino acid, has been reported to modulate metabolism and growth in various species of animals; however, whether the action of cysteamine involves adiponectin and its receptors is unknown. The objective of the present study was therefore to investigate the effect of dietary cysteamine on the expression of AdipoR1/R2 in different tissues, in association with the alterations in endocrine and metabolic status. Rats were fed either of the diets supplemented with 0 or 700 mg/kg cysteamine feed additive (containing 30% of cysteamine hydrochloride) for 4 weeks, and the expression of adiponectin and its receptors in adipose tissue, AdipoR1 and AdipoR2 in liver, gastrocnemius, and soleus muscle was determined, in association with the growth performance and serum concentrations of hormones and metabolites. A temporal trend of increase in growth rate and the ratio of feed consumption relative to body weight gain was observed in the second week of cysteamine supplementation. Serum concentrations of insulin and TNF-alpha increased, while serum levels of triglycerides, FFA, and total cholesterol decreased significantly 4 weeks after cysteamine treatment. Leptin and GH remained unaffected. Cysteamine supplementation increased mRNA expression of AdipoR1 in adipose tissue, gastrocnemius, and soleus muscle as well as that of AdipoR2 in soleus muscle and adipose tissue. Nevertheless, hepatic expression of AdipoR1 and AdipoR2 was not influenced. Despite a numeric increase, no significant alteration in adiponectin mRNA expression in adipose tissue was observed. In conclusion, dietary supplementation of cysteamine modulates the endocrine and metabolic status of rats, which may involve the tissue-specific responses of adiponectin receptors at the level of mRNA transcription.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.